Search

Ovarian cancer is the most fatal gynecologic malignancy. Low-grade type represents only 2-5% of all ovarian cancer pathological types. Its clinical characteristics, growth pattern, and response to treatment are distinct from high-grade serous ovarian carcinoma. In this study, we retrospectively evaluated the clinical features, prognostic factors, and survival of patients diagnosed with low-grade serous ovarian cancer from a tertiary cancer centre. This is a retrospective study where all patients diagnosed with lowgrade serous ovarian cancer (LGSOC) who presented to a tertiary cancer centre from July 2015 to August 2021 were included. Forty-two patients with low-grade ovarian serous carcinoma were enrolled. The mean age of the patients was 50.17 ± 10.91 years, while the mean Body Mass Index (BMI) was 32.96 ± 6.02 kg/m2. Primary optimal debulking was performed in 18 patients, while interval cytoreduction was done in 17 patients. Suboptimal debulking was performed in 5 patients. Neoadjuvant chemotherapy was administered in 19 patients (45.2%). The median overall survival of LGSOC patients was 95.58 (73.37-117.79) months while the median Progression free survival (PFS) was 56.54 (38.15-74.94) months. Primary cytoreductive surgery is still the cornerstone of the management of LGSOC patients. Neoadjuvant chemotherapy could be a predictor of worse progression-free survival in LGSOC patients presented with advanced disease stage. [ABSTRACT FROM AUTHOR]

Background: Ovarian cancer is the most prevalent gynecologic malignancy in Egypt. Although metastasis from ovarian cancer is common, there are still sites with rarely reported deposits as non-regional nodes, bone, and brain. Method: We retrospectively recruited a group of patients over a 7-year period from the data system of a cancer center. All the recruited patients suffered from a rare distant metastasis from ovarian cancer. We used statistical software (SPSS) for the analysis of the study results. Continuous variables were presented as mean and standard deviation, if normally distributed, or median and range when non-normally distributed. Independent samples t-test was utilized to compare parametric data, whereas nonparametric data were compared through the use of the Mann-Whitney U test. Categorical data were compared with Pearson's Chi-square test or Fischer-Exact test when appropriate. A P-value < 0.05 was considered to be statistically significant. Results: Nearly half of the patients already had metastasis at the time of the initial presentation, while the rest developed it during the disease course. Debulking was feasible in nearly half of the patients with long overall and progression-free survival. Tumors with non-regional nodal metastases seemed to have excellent survival. Conclusion: We could recommend offering these patients optimal debulking and considering those with a non-regional nodal spread as having a curable disease. [ABSTRACT FROM AUTHOR]